Multiple Myeloma - Maintenance Therapy vs. Placebo Study (06-031T)
CALGB 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC # 703813, IND #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Protocol ID
06-031T
Protocol Description
The purpose of this study is to find out what effects (good and bad) treatment with an investigational agent known as CC-5013 has on subjects with multiple myeloma following an autologous stem cell transplant. CC-5013 has not been approved by the Food and Drug Administration (FDA), and its use in this study is experimental.
Eligibility Criteria
Patients with multiple myeloma having autologous stem cell transplant
Primary Investigator(s)
- Ruthee-Lu Bayer, MD